- Home
- KRSP vs ADCT Comparison
KRSP vs ADCT Comparison
Compare KRSP & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KRSP | ADCT |
|---|---|---|
| Founded | 2025 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 477.0M | 484.4M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | KRSP | ADCT |
|---|---|---|
| Price | $10.35 | $4.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 14.2K | ★ 801.2K |
| Earning Date | 01-01-0001 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $70,837,000.00 |
| Revenue This Year | N/A | $14.96 |
| Revenue Next Year | N/A | $1.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.84 |
| 52 Week Low | $10.21 | $1.05 |
| 52 Week High | $10.70 | $4.80 |
Technical Indicators
Market Signals| Indicator | KRSP | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 51.69 | 54.53 |
| Support Level | $10.30 | $3.93 |
| Resistance Level | $10.50 | $4.71 |
| Average True Range (ATR) | 0.02 | 0.24 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 55.56 | 33.56 |
Price Performance
Historical ComparisonAbout KRSP Rice Acquisition Corporation 3
Rice Acquisition Corp 3 is a blank check company.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).